What is Zacks Research's Estimate for TBPH Q1 Earnings?

Key Points

• Zacks Research estimates TBPH will earn $0.01 per share in Q1 2028 and rates the stock as a Strong-Buy.
• Zacks forecasts FY2028 EPS of $0.59, while the current consensus for the company’s full-year earnings is ($1.09) per share.
• Analyst sentiment is mixed (2 Strong Buy, 2 Buy, 4 Hold), yielding an average rating of "Moderate Buy" and a mean price target of $21.83.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Analysts at Zacks Research issued their Q1 2028 earnings estimates for shares of Theravance Biopharma in a research note issued to investors on Thursday, April 9th. Zacks Research analyst Team forecasts that the biopharmaceutical company will earn $0.01 per share for the quarter. Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma's FY2028 earnings at $0.59 EPS.

Several other brokerages have also recently commented on TBPH. BTIG Research reissued a "buy" rating and set a $21.00 price target on shares of Theravance Biopharma in a research report on Friday, March 20th. HC Wainwright boosted their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Weiss Ratings cut shares of Theravance Biopharma from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Friday. Wall Street Zen cut shares of Theravance Biopharma from a "strong-buy" rating to a "buy" rating in a research report on Monday, April 6th. Finally, B. Riley Financial boosted their price target on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 7th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $21.83.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $16.35 on Monday. The firm has a market cap of $841.86 million, a PE ratio of 8.05 and a beta of 0.17. Theravance Biopharma has a 1-year low of $8.16 and a 1-year high of $21.03. The company has a fifty day moving average price of $16.75 and a 200 day moving average price of $17.08.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. The trade was a 11.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its stake in Theravance Biopharma by 51.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,133 shares of the biopharmaceutical company's stock valued at $77,000 after buying an additional 1,408 shares during the last quarter. Pacer Advisors Inc. acquired a new position in Theravance Biopharma in the 4th quarter valued at about $6,342,000. Invesco Ltd. grew its stake in Theravance Biopharma by 622.2% in the 4th quarter. Invesco Ltd. now owns 177,946 shares of the biopharmaceutical company's stock valued at $3,329,000 after buying an additional 153,306 shares during the last quarter. Mackenzie Financial Corp bought a new stake in Theravance Biopharma in the 4th quarter valued at about $705,000. Finally, Susquehanna Portfolio Strategies LLC boosted its holdings in Theravance Biopharma by 208.8% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 43,350 shares of the biopharmaceutical company's stock valued at $811,000 after purchasing an additional 29,313 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.